|Monday, January 03 2011|
MIVAC Development receives verification grant from GöteborgBIO and Sahlgrenska Science Park (SSP).
The grant will enable MIVAC Development to further develop and verify the therapeutic and commercial potential of a newly discovered monoclonal antibody specific for the toxic confomation of Aβ aggregates. The antibody was developed using the AβCCTM technology platform (patent pending approval). Click here to view the GöteborgBIO/SSP press release (in swedish).